A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
NCT ID: NCT04885712
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
378 participants
INTERVENTIONAL
2021-05-28
2023-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
NCT06571591
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
NCT03499704
Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes
NCT05591235
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
NCT00727857
Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes
NCT00754403
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo
Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg Pioglitazone 30mg placebo
Metformin≥1000mg
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 15mg
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 30mg Placebo
Subjects take the investigational products once a day for 24 weeks.
Dapagliflozin 10mg
Subjects take the investigational products once a day for 24 weeks.
Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo
Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 30mg Pioglitazone 15mg placebo
Metformin≥1000mg
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 30 mg
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 15mg Placebo
Subjects take the investigational products once a day for 24 weeks.
Dapagliflozin 10mg
Subjects take the investigational products once a day for 24 weeks.
Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo
Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg placebo Pioglitazone 30mg placebo
Metformin≥1000mg
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 15mg Placebo
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 30mg Placebo
Subjects take the investigational products once a day for 24 weeks.
Dapagliflozin 10mg
Subjects take the investigational products once a day for 24 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin≥1000mg
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 15mg
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 30 mg
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 15mg Placebo
Subjects take the investigational products once a day for 24 weeks.
Pioglitazone 30mg Placebo
Subjects take the investigational products once a day for 24 weeks.
Dapagliflozin 10mg
Subjects take the investigational products once a day for 24 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adults aged 19 years or older.
3. Those diagnosed with type 2 diabetes mellitus.
4. Subjects taking constant doses of ≥1000mg of Metformin and 10 mg of Dapagliflozin for more than 8 weeks at Visit 1 (regardless of dosage forms (immediate-release and sustained-release) and single agent or combination drug.)
5. Subjects with 7% ≤ HbA1c ≤ 10.5% at Visit 1 and Visit 2
6. Subjects able to understand the study, comply with study procedures, and attend all scheduled visits.
Exclusion Criteria
2. Medication compliance is \<70% or \>120% for each BR3003D, BR3003C, BR3003A-2, and BR3003B-2 during the Run-in period at Visit 2.
3. Patients with other types of diabetes instead of type 2 diabetes (e.g., type 1 diabetes, secondary diabetes, or congenital renal glycosuria).
4. Patients with uncontrolled, severe diabetic complications (e.g., proliferative diabetic retinopathy uncontrolled despite medication and severe diabetic neuropathy)
5. Those who suffered from acute or chronic metabolic acidosis within 3 months as of Visit 1, including lactic acidosis and diabetic ketoacidosis.
6. Those with \> 40 kg/m2 of BMI measured at Visit 1.
7. Those with uncontrolled hypertension at Visit 1 or Visit 2 (SBP \> 180 mmHg or DBP \> 110 mmHg).
8. Those diagnosed with cardiovascular diseases (myocardial infarction, stroke, unstable angina, and transient ischemic attack (TIA)) or undergo revascularization within 3 months as of Visit 1
9. Those with heart failure (NYHA class II\~IV) or who had suffered from heart failure.
10. Those who suffered from gastrointestinal diseases that may affect the absorption, distribution, metabolism, and excretion of investigational products or had underwent surgery;
11. Those who underwent surgery requiring general anesthesia within 4 weeks as of Visit 1 or who are scheduled to receive such surgery within 4 weeks after the study ends
12. Those with a history of malignant tumor within 5 years as of Visit 1
13. Those who have a clinically significant liver disease
14. Those who have a clinically significant renal disease
15. Those with clinically significant hematuria detected at Visit 1 or Visit 2
16. Those with chronic diseases requiring the continued use of systemic steroid or immunosuppressants (oral administration, injection, or inhalation).
17. Patients with pituitary insufficiency or adrenal insufficiency.
18. Those with clinically significant severe infection or trauma based on an investigator's judgement.
19. Patients with AIDS.
20. Patients with acute or chronic diseases that may cause histotoxic hypoxia such as respiratory failure and shock.
21. Those who need treatment due to dehydration caused by persistent diarrhea and vomiting or at a risk of fluid volume depletion.
22. Those who have been administered with the following drugs or expected to require the continued administration during the study period:
* Those administered with systemic steroid agents (Prednisolone, \>30 mg/day) within 2 weeks as of Visit 1.
* Those being administered with thyroid medications and whose dose has been modified within 6 weeks as of Visit 1 (however, dose reduction is accepted.)
* Those being administered with diuretics and whose dose has been modified within 8 weeks as of Visit 1 however, dose reduction is accepted.)
* Those who have been administered with antidiabetics other than Metformin and Dapagliflozin within 8 weeks as of Visit 1.
* Those who have been administered with obesity drugs (e.g., phentermine, phendimetrazine, diethylpropion, and mazindol) within 12 weeks as of Visit 1.
* Those who need to take prohibited concomitant medications stated here during the study period.
23. Those with history of alcohol or drug abuse within 1 year as of Visit 1.
24. Those who had allergic reaction to main ingredients or components of the investigational products.
25. Those who had genetic disorders such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
26. Females who are pregnant or breastfeeding.
27. Patients planning to become pregnant or of childbearing potential, but not using any recognized contraceptive method
28. Those who are currently participating in other ongoing clinical studies or those who have taken the investigational products from other clinical studies within 12 weeks as of Visit 1
29. Those who are judged unsuitable for the study by a principal investigator or investigators.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Woo-je Lee
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cho YK, Kim KS, Lee BW, Hong JH, Yu JM, Lim S, Kim YA, Lee CB, Kim SS, Kwak SH, Lee WJ. Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study. Clin Ther. 2024 Sep;46(9):662-669. doi: 10.1016/j.clinthera.2024.06.023. Epub 2024 Jul 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-DPC-CT-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.